{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-110654","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.902135+00:00","generated_at":"2026-06-09T16:26:44.599253+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Sagimet furnishes updated investor presentation on NASH, acne, cancer pipeline","bullets":["Filed updated slide deck under Item 7.01 for use in investor meetings.","Presentation targets metabolic dysfunction therapies for NASH, acne, and cancer.","No specific financial or clinical data from the deck was disclosed in the 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-110654","json":"https://secwatch.observer/filing/0001104659-23-110654.json","markdown":"https://secwatch.observer/filing/0001104659-23-110654.md","text":"https://secwatch.observer/filing/0001104659-23-110654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923110654/0001104659-23-110654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923110654/tm2328875d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T16:26:44.599253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}